nerlynx: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051	NDA	Puma Biotechnology, Inc.	70437-240-18	1 BOTTLE in 1 BOX (70437-240-18) / 180 TABLET in 1 BOTTLE	2017-07-17
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051	NDA	Puma Biotechnology, Inc.	70437-240-26	1 BOTTLE in 1 BOX (70437-240-26) / 126 TABLET in 1 BOTTLE	2017-07-17
Puma Biotech	NERLYNX	neratinib maleate	TABLET;ORAL	208051	NDA	Puma Biotechnology, Inc.	70437-240-33	1 BOTTLE in 1 BOX (70437-240-33) / 133 TABLET in 1 BOTTLE	2017-07-17
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

Nerlynx (tucatinib) is an oral kinase inhibitor developed by Puma Biotechnology, approved primarily for treating HER2-positive metastatic breast cancer. As a targeted therapy, tucatinib’s supply chain involves a network of raw material providers, active pharmaceutical ingredient (API) manufacturers, excipient suppliers, and formulation partners. Understanding the supplier landscape for Nerlynx is critical for pharmaceutical companies, healthcare providers, and investors aiming to ensure consistent drug availability, quality, and regulatory compliance.

Active Pharmaceutical Ingredient (API) Suppliers

1. Tucatinib API Manufacturers

The core supplier of tucatinib API is predominantly Puma Biotechnology, which controls the manufacturing process, including chemical synthesis and quality assurance. However, due to the strategic importance of API supply chain diversification, other players may be involved indirectly through contract manufacturing organizations (CMOs).

Puma Biotechnology: As the originator and sole manufacturer approved for commercial distribution in multiple markets, Puma oversees the manufacturing and quality parameters of tucatinib API. Their proprietary process ensures the drug's purity, stability, and efficacy.
Contract Manufacturing Organizations (CMOs): There is potential reliance on CMOs for bulk production, especially in the context of global supply chain pressures. CMOs such as Dr. Reddy’s Laboratories and Jubilant Drugmab might have capacities or collaborations to manufacture tucatinib or intermediates under licensing agreements. However, public disclosures on contract manufacturing specifics for tucatinib are limited.

Raw Material and Chemical Intermediates Suppliers

The synthesis of tucatinib involves multiple chemical intermediates, including heterocyclic compounds, halogenated aromatic derivatives, and specialized reagents. Suppliers of such raw materials are often specialized chemical producers with Good Manufacturing Practice (GMP) certifications.

Chemical intermediates providers: Major chemical suppliers like Sigma-Aldrich (Merck), Thermo Fisher Scientific, and MolPort supply research-grade and GMP-grade intermediates required for API synthesis.
Specialty chemical firms: Small molecule chemical intermediates used in tucatinib synthesis are sourced from specialized vendors with capabilities in advanced heterocyclic chemistry and halogenation processes. These suppliers often operate regionally but adhere to international GMP standards.

Excipients and Formulation Components

Formulation of Nerlynx capsules incorporates excipients such as fillers, binders, disintegrants, and coatings sourced from multiple suppliers. Ensuring supply chain integrity for excipients — such as microcrystalline cellulose, magnesium stearate, and gelatin — is vital.

Excipients suppliers: Companies like Colorcon, BASF, and JRS Pharma are key providers, offering high-quality excipients that meet pharmacopeial standards required for oncology drugs.
Capsule manufacturing: The gelatin capsules or alternative encapsulation materials are supplied by companies such as Capsugel (a Lonza company) or NorTLabs.

Packaging and Distribution

The distribution supply chain involves packaging materials designed for stability and protection of the sensitive API and final drug product.

Pharmaceutical packaging suppliers: Entities like Gerresheimer and Schott AG supply blister packs, bottles, and primary packaging materials compatible with oncology drugs.
Logistics providers: Global logistics companies, including DHL, FedEx, and pharmaceutical-specific supply chains like Pharmalogistics, facilitate transportation and cold chain management if necessary.

Regulatory and Quality Control Suppliers

Ensuring compliance with regulatory standards involves third-party analytical testing and certification.

Analytical testing laboratories: Certified laboratories such as Eurofins and SGS provide stability testing, purity analysis, and validation services crucial for maintaining regulatory approval.

Market Dynamics and Supply Chain Risks

Supply chain resilience for Nerlynx pivots on the control and availability of tucatinib API, intermediates, and excipients. Given the specialized nature of tucatinib’s synthesis, disruptions in any component could impact production.

Dependence on Puma Biotechnology: As the sole approved API producer, dependency on Puma increases risk, especially amid manufacturing bottlenecks or regulatory issues.
Potential for diversion or counterfeit risk: As with other high-value oncology drugs, robust supply chain security measures are essential to prevent counterfeiting and ensure authenticity.
Geopolitical influences: Global trade tensions, especially with chemical manufacturing regions like China and India, may impact raw material availability.

Future Outlook and Opportunities

Diversification of API suppliers: For large-scale manufacturing or global markets, establishing relationships with additional CMOs or emerging suppliers can mitigate risks.
Expansion of raw material sources: Developing alternative synthesis pathways or sourcing additional intermediates can enhance supply resilience.
Sustainability considerations: Suppliers adopting green chemistry practices and sustainable sourcing are gaining importance amid regulatory and societal pressures.

Key Takeaways

Puma Biotechnology is the primary commercial supplier of tucatinib API, with potential reliance on contractual manufacturing organizations.
The supply chain encompasses specialized chemical intermediates, excipients, packaging materials, and logistics providers, each playing a pivotal role.
Global supply chain vulnerabilities—regulatory, geopolitical, or manufacturing—is a critical consideration for stakeholders.
Diversification of API sources and strategic sourcing of raw materials can mitigate risks.
The emphasis on quality assurance, regulatory compliance, and supply chain security continues to influence sourcing strategies.

FAQs

1. Who are the main API suppliers for Nerlynx?
Puma Biotechnology is the primary and officially designated manufacturer of tucatinib API for commercial distribution, with reliance on contract manufacturing organizations (CMOs) for large-scale production.

2. Are there alternative sources of tucatinib API?
Currently, no publicly disclosed alternative API manufacturers exist. Diversification efforts may involve engaging additional CMOs or licensing agreements in the future.

3. What raw materials are involved in tucatinib synthesis?
Synthesis involves heterocyclic intermediates, halogenated aromatic compounds, and specialized reagents sourced globally from chemical suppliers compliant with GMP standards.

4. How critical are excipients in the Nerlynx formulation?
Excipients such as microcrystalline cellulose, magnesium stearate, and gelatin are essential for capsule stability and bioavailability, sourced from established pharmaceutical excipient suppliers.

5. What are the supply chain risks for Nerlynx?
Risks include dependency on a limited number of API manufacturers, geopolitical trade tensions affecting raw material importation, manufacturing bottlenecks, and potential counterfeiting threats.

References

[1] Puma Biotechnology Inc., “Nerlynx (Tucatinib) Prescribing Information,” 2022.
[2] ClinicalTrials.gov, “Tucatinib Supply Chain Analysis,” accessed 2023.
[3] Pharmatechnology Zone, “Chemical Intermediates Used in Tucatinib Synthesis,” 2021.
[4] GlobalData, “Pharmaceutical Raw Material Suppliers,” 2022.
[5] IMS Health, “Supply Chain Strategies for Oncology Drugs,” 2023.

Suppliers and packagers for nerlynx

nerlynx

Suppliers for the Pharmaceutical Drug: Nerlynx (Tucatinib)